Literature DB >> 34926056

Dynamic Profile of Prognostic Hematologic Indicators in Patient Under Intensive Care for COVID-19 Disease: A One-Year Study at a Tertiary Care Centre in South India.

Jayalakshmi Balasubramanian1, Febe Renjitha Suman2, Immanuel Ratan Stephen1, Sri Gayathri Shanmugam1, Rajkumar Mani3, Bhargavi Mathan3, Lakshmi P3.   

Abstract

Introduction Viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS COV-2) releases cytokines which result in neutrophils migration to the bloodstream and cytotoxic effect on lymphocytes. The ongoing pathology is reflected in the derangement of blood cells and the variations and calculations based on them that help in assessing the severity of the disease and prognosis. Aim This study aimed to compare the differences in the dynamic changes of the blood cells among survivors and non-survivors of COVID-19 disease so that cut-offs can be arrived at to aid triage at the intensive care unit (ICU) and to predict mortality.  Material and methods A one-year study was conducted on patients hospitalized in the ICU. The demography and laboratory values of neutrophils and lymphocytes in percentages and absolute values, and platelet count in numbers were retrieved for eight consecutive values. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) was calculated from absolute counts. Statistical analysis was done using the Chi-Square test and Mann-Whitney test and a P-value of <0.05 is considered significant. The comparison was done between survivors and non-survivors. Result Among the 3142 patients admitted for COVID-19 disease, 7.6% required ICU care of whom 65.5% survived and 35.5% succumbed to the illness. Survivors were younger and comparable between both sexes. Though both groups had an ascending trend of neutrophils, lymphocytes, NLR, and PLR, the baseline characteristics were significantly lower in those who survived on a day-to-day basis. Neutrophilia above 80%, NLR 7.96, PLR 200 predicted the need for admission in ICU. Neutrophilia of 87% and lymphopenia of 10% were associated with adverse outcomes (mortality). Mortality can be predicted when neutrophil rises above 93% or lymphocytes fall below 5.2%. An initial NLR of 7.96 and PLR of 160 as well as peak NLR of 12.29 and peak PLR 400 predict mortality. Conclusion Serial blood counts are essential for hospitalized patients with COVID-19 for early triaging, and to assess severity and prognosis. The NLR of 6.7 and PLR of 160 require intensive care. The dynamic increase of NLR and PLR show worsening of the disease process and NLR of 40.95 and PLR of 400 predict mortality.
Copyright © 2021, Balasubramanian et al.

Entities:  

Keywords:  covid 19; medical intensive care unit (micu); neutrophil to lymphocyte ratio (nlr); neutrophilia; platelet to lymphocyte ratio (plr)

Year:  2021        PMID: 34926056      PMCID: PMC8671058          DOI: 10.7759/cureus.19585

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  15 in total

1.  Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019.

Authors:  Xiurong Ding; Yanhua Yu; Bichao Lu; Jianbo Huo; Ming Chen; Yanfang Kang; Jinli Lou; Zhizhong Liu
Journal:  Clin Chem Lab Med       Date:  2020-07-28       Impact factor: 3.694

2.  Neutrophil-to-lymphocyte ratio, a critical predictor for assessment of disease severity in patients with COVID-19.

Authors:  Lei Liu; Yaqiong Zheng; Liping Cai; Wanlei Wu; Shi Tang; Yinjuan Ding; Wanbing Liu; Guomei Kou; Zhou Xiong; Shengdian Wang; Shangen Zheng
Journal:  Int J Lab Hematol       Date:  2020-10-25       Impact factor: 2.877

3.  Neutrophil/lymphocyte ratio-A marker of COVID-19 pneumonia severity.

Authors:  Mehr Muhammad Imran; Umair Ahmad; Umer Usman; Majid Ali; Aamir Shaukat; Noor Gul
Journal:  Int J Clin Pract       Date:  2021-01-12       Impact factor: 2.503

4.  Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio and Their Role as Predictors of Disease Severity of Coronavirus Disease 2019 (COVID-19).

Authors:  Rohit Jain; Arun Gopal; Basant Kumar Pathak; Sourya Sourabh Mohakuda; Tvsvgk Tilak; Anchit Raj Singh
Journal:  J Lab Physicians       Date:  2021-02-22

5.  The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China.

Authors:  Jianhong Fu; Jindan Kong; Wei Wang; Meiying Wu; Lin Yao; Zhaoyue Wang; Jun Jin; Depei Wu; Xin Yu
Journal:  Thromb Res       Date:  2020-05-06       Impact factor: 3.944

6.  Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage.

Authors:  Jingyuan Liu; Yao Liu; Pan Xiang; Lin Pu; Haofeng Xiong; Chuansheng Li; Ming Zhang; Jianbo Tan; Yanli Xu; Rui Song; Meihua Song; Lin Wang; Wei Zhang; Bing Han; Li Yang; Xiaojing Wang; Guiqin Zhou; Ting Zhang; Ben Li; Yanbin Wang; Zhihai Chen; Xianbo Wang
Journal:  J Transl Med       Date:  2020-05-20       Impact factor: 5.531

7.  Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio as Predictors of the Early Requirement of Mechanical Ventilation in COVID-19 Patients.

Authors:  Parvathy R Nair; Souvik Maitra; Bikash R Ray; Rahul K Anand; Dalim K Baidya; Rajeshwari Subramaniam
Journal:  Indian J Crit Care Med       Date:  2020-11

8.  Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality.

Authors:  Elnaz Vafadar Moradi; Ali Teimouri; Ramin Rezaee; Negar Morovatdar; Mahdi Foroughian; Parvaneh Layegh; Behrang Rezvani Kakhki; Seyed Reza Ahmadi Koupaei; Vahideh Ghorani
Journal:  Am J Emerg Med       Date:  2020-12-04       Impact factor: 2.469

9.  Neutrophil-Lymphocyte Ratio in Patients with COVID-19 as a Simple Tool to Predict Requirement of Admission to a Critical Care Unit.

Authors:  Sagar S Maddani; Nitin Gupta; Shashikiran Umakanth; Sowmya Joylin; Kavitha Saravu
Journal:  Indian J Crit Care Med       Date:  2021-05

10.  WHO Declares COVID-19 a Pandemic.

Authors:  Domenico Cucinotta; Maurizio Vanelli
Journal:  Acta Biomed       Date:  2020-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.